Q2 2025 EPS Estimates for Quest Diagnostics Incorporated (NYSE:DGX) Increased by Analyst

Quest Diagnostics Incorporated (NYSE:DGX) – Zacks Research increased their Q2 2025 EPS estimates for shares of Quest Diagnostics in a note issued to investors on Tuesday, September 24th. Zacks Research analyst M. Mondal now expects that the medical research company will earn $2.51 per share for the quarter, up from their prior estimate of $2.50. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.45 EPS, FY2025 earnings at $9.57 EPS, Q1 2026 earnings at $2.58 EPS and FY2026 earnings at $10.43 EPS.

A number of other brokerages have also recently issued reports on DGX. Citigroup raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their target price for the company from $145.00 to $165.00 in a report on Wednesday, July 10th. Evercore ISI started coverage on shares of Quest Diagnostics in a report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target on the stock. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Barclays increased their price target on shares of Quest Diagnostics from $144.00 to $154.00 and gave the company an “equal weight” rating in a report on Tuesday, August 27th. Finally, Piper Sandler increased their price target on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a report on Monday, July 29th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $154.33.

Quest Diagnostics Stock Up 0.2 %

Shares of DGX stock opened at $154.71 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.91 and a current ratio of 1.00. The firm’s 50-day moving average is $151.11 and its 200-day moving average is $141.63. The stock has a market cap of $17.19 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 2.80 and a beta of 0.89. Quest Diagnostics has a 52-week low of $119.59 and a 52-week high of $159.36.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.31 by $0.04. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. Quest Diagnostics’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.30 EPS.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.94%. Quest Diagnostics’s payout ratio is presently 40.38%.

Insiders Place Their Bets

In related news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the sale, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the sale, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the sale, the senior vice president now owns 11,459 shares in the company, valued at approximately $1,756,206.34. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.

Institutional Trading of Quest Diagnostics

Large investors have recently made changes to their positions in the company. Rothschild Investment LLC bought a new position in Quest Diagnostics in the 2nd quarter valued at approximately $26,000. Spartan Planning & Wealth Management acquired a new position in Quest Diagnostics in the 4th quarter valued at approximately $31,000. Innealta Capital LLC bought a new position in shares of Quest Diagnostics during the second quarter valued at $31,000. Larson Financial Group LLC lifted its holdings in shares of Quest Diagnostics by 77.5% during the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock worth $31,000 after purchasing an additional 100 shares during the period. Finally, Riverview Trust Co bought a new stake in shares of Quest Diagnostics in the first quarter worth $33,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.